+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Triphenylmethane derivatives have high in vitro and in vivo activity against the main causative agents of cutaneous leishmaniasis



Triphenylmethane derivatives have high in vitro and in vivo activity against the main causative agents of cutaneous leishmaniasis



Plos one 8(1): E51864



The current standard of care for cutaneous leishmaniasis (CL) is organic antimonial compounds, but the administration of these compounds is complicated by a low therapeutic - toxic index, as well as parenteral administration. Thus, there is an urgent need for the development of new and inexpensive therapies for the treatment of CL. In this study, we evaluate the activity of the triphenylmethane (TPM) class of compounds against three species of Leishmania which are pathogenic in humans. The TPM have a history of safe use in humans, dating back to the use of the original member of this class, gentian violet (GV), from the early 20(th) century. Initially, the in vitro efficacy against Leishmania (Viannia) braziliensis, L. (Leishmania) amazonensis and L. (L.) major of 9 newly synthesized TPM, in addition to GV, was tested. Inhibitory concentrations (IC) IC(50) of 0.025 to 0.84 µM had been found in promastigotes in vitro assays. The four most effective compounds were then tested in amastigote intracellular assays, resulting in IC(50) of 0.10 to 1.59 µM. A high degree of selectivity of antiparasitic activity over toxicity to mammalian cells was observed. Afterwards, GV and TPM 6 were tested in a topical formulation in mice infected with L. (L.) amazonensis leading to elimination of parasite burdens at the site of lesion/infection. These results demonstrated that TPM present significant anti-leishmanial activities and provide a rationale for human clinical trials of GV and other TPM. TPM are inexpensive and safe, thus using them for treatment of CL may have a major impact on public health.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056693553

Download citation: RISBibTeXText

PMID: 23341885

DOI: 10.1371/journal.pone.0051864


Related references

The extra-burrow activity of the vectors of the causative agents of zoonotic cutaneous leishmaniasis. Meditsinskaia Parazitologiia i Parazitarnye Bolezni .(5): 37-43, 1993

Inhibition by Dications of in vitro growth of Leishmania major and Leishmania tropica: causative agents of old world cutaneous leishmaniasis. Journal of Parasitology 94(3): 743-749, 2008

In Vitro Antifungal Activity of Hexahydropyrimidine Derivatives against the Causative Agents of Dermatomycosis. Thescientificworldjournal 2017: 1207061, 2017

Experimental infection with a Mexican strain of the causative agents of cutaneous leishmaniasis. Salud Publica de Mexico 10(2): 159-171, 1968

Seasonal changes in the population structure of the causative agents of zoonotic cutaneous leishmaniasis in its virulent properties. Meditsinskaia Parazitologiia i Parazitarnye Bolezni .(4): 32-38, 1986

The sesquiterpene (-)-α-bisabolol is active against the causative agents of Old World cutaneous leishmaniasis through the induction of mitochondrial-dependent apoptosis. Apoptosis 21(10): 1071-1081, 2016

Activity of physalins purified from Physalis angulata in in vitro and in vivo models of cutaneous leishmaniasis. Journal of Antimicrobial ChemoTherapy 64(1): 84-87, 2009

Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo. Infection and Immunity 59(8): 2839-2842, 1991

Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World. Clinical and Vaccine Immunology 14(9): 1173-1181, 2007

Method of obtaining antisera with a high titer of antibodies to the causative agent of cutaneous leishmaniasis in rabbits. Vestnik Dermatologii i Venerologii 1978(5): 80-84, 1978

In vitro and in vivo antileishmanial activity of Artemisia annua L. leaf powder and its potential usefulness in the treatment of uncomplicated cutaneous leishmaniasis in humans. Revista Da Sociedade Brasileira de Medicina Tropical 50(1): 52-60, 2017

A comparison of the in vivo and in vitro activity of pentostam of Chinese origin and glucantime against Leishmania brasiliensis isolated from patients with cutaneous leishmaniasis in Vitoria, ES, Brazil. Memorias do Instituto Oswaldo Cruz 93(Suppl. 2): 293, 1998

Distamycin a derivatives in vitro and in vivo activity of a new class of antitumor agents. Proceedings of the American Association for Cancer Research Annual Meeting 29: 330, 1988

In vitro and in vivo activity of 1-aryl-3-(2-chloroethyl) urea derivatives as new antineoplastic agents. Anticancer Research 8(4): 595-598, 1988

Some structure activity relationships of phencyclidine derivatives as anticholinergic agents in vitro and in vivo. Progress in Clinical and Biological Research 27: 91, 1979